DiaPep277® and immune intervention for treatment of type 1 diabetes.

Abstract

Type 1 diabetes is a chronic immune-mediated disease resulting in destruction of insulin-producing β-cells. Several studies have been performed aiming to halt disease progression after diagnosis; to reduce the increased diabetes risk in islet-autoantibody positive subjects; and to prevent the onset of β-cell autoimmunity in subjects genetically at risk but without autoantibodies. Whereas secondary prevention trials failed, trials in newly diagnosed patients have shown partial success in preserving C-peptide. These studies target T-cells and inflammation and make use of antigen-specific immune modulation or stem cell approaches. However, thus far no immune-based therapeutic regimen has cured type 1 diabetes after its clinical onset or has stabilized the decline of C-peptide to achieve the status of an approved drug. This review summarizes immune intervention trials and the current knowledge of DiaPep277® peptide as a form of immune intervention in type 1 diabetes.

• Authors: Nanette C Schloot, Irun R Cohen
• Journal: Clinical immunology (Orlando, Fla.) (Clin Immunol) Vol. 149 Issue 3 Pg. 307-16 (Dec 2013) ISSN: 1521-7035 [Electronic] United States
• PMID: 24090708 (Publication Type: Journal Article, Review)
• Copyright: © 2013.

Chemical References

• Autoantibodies
• C-Peptide
• Chaperonin 60
• DiaPep 277
• Hypoglycemic Agents
• Peptide Fragments

Topics

• Autoantibodies (immunology)
• Autoimmunity
• C-Peptide (immunology, metabolism)
• Chaperonin 60 (therapeutic use)
• Clinical Trials as Topic
• Diabetes Mellitus, Type 1 (immunology, therapy)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Immunotherapy
• Islets of Langerhans (drug effects, immunology, pathology)
• Peptide Fragments (therapeutic use)
• T-Lymphocytes (drug effects, immunology, pathology)
• Treatment Outcome